Vorinostat
As of the edition of 20 October 2026, Vorinostat is a small molecule: marketed, first approved in 2006 (US); acts on HDAC1, HDAC2 and HDAC3 and 1 more; US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Zolinza
- First approved
- 6 October 2006 (US)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Merck & Co.
- Registered trials
- 261, 71 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Urinary and reproductive; Nervous system; Lungs and airways
US protection
US protection ends in 2027.
The last listed US drug-substance patent ends in 2027. The application that gives this date is held by Merck & Co..
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Vorinostat.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 4 | 0 | 1 |
| Phase 1 | 111 | 78 | 12 | 19 |
| Phase 2 | 136 | 67 | 14 | 49 |
| Phase 3 | 7 | 4 | 1 | 2 |
| All trials | 261 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Applicant and Lead sponsor of trials | 2004 to now |